Elena Smith is Analytical CMC Leader at Sanofi and establish the strategy for control of new vaccines in mRNA platform. Dr Smith is also Industry Lead of joint WHO/IFPMA technical working group on potency and reagents for Influenza Vaccine (traditional and mRNA platforms) contributing to pandemic preparedness. Dr Smith joined Sanofi (Protein Sciences) in 2013 and led Quality Control for the commercialization of the new product, world's first recombinant Influenza vaccine Flublok, with several seasons of product scale-up on the market. Elena contributed to strategy for product control and characterization for various products spanning from Phase 1 to Commercial including bringing to the market Flublok Quadrivalent/Supemtek and COVID 19 vaccine booster - VidPrevtin. Dr. Smith obtained her Ph.D. in Molecular Biology following completion of postdoctoral training in renowned Laboratory of Molecular Biology at NIDDK U.S. National Institutes of Health and fellowship at U.S. Food and Drug Administration.